• 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital and Institute, Beijing 100142, P.R.China;
  • 2. Department of Haematology, Key Laboratory of Haematology of Hebei Province, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, P.R.China;
  • 3. Department of Molecular and Cellular Physiology, Institute of Medicine, Academic Assembly, Shinshu University, Nagano, 3908621, Japan;
CAO Xueshan, Email: cxs_cn@foxmail.com
Export PDF Favorites Scan Get Citation

Objectives To collect the methodology and original articles on the published cohort multiple randomized controlled trial (cmRCT), and evaluate the development and application of cmRCT.Methods PubMed, EMbase, CNKI, WanFang Data and CBM databases were electronically searched to collect studies on cmRCT from inception to September 2019. Two reviewers independently screened literature, extracted data and assessed risk of bias of included studies, then qualitative analysis was conducted.Results A total of 21 studies were enrolled, including 5 original studies and 16 methodology studies. The design of cmRCT was proposed in year 2010 and continuous progress was observed, including aspect of informed consent and statistical analysis, etc. This design has been mainly utilized for chronic diseases (oncology etc.) in Europe; most of these ongoing studies were unpublished. However, to our knowledge, there were none published Chinese original studies or protocols using cmRCT design.Conclusions cmRCT design has been continuously developed and applied since its introduction. This design can be considered in Chinese studies based on Chinese large cohorts to provide more evidence for disease prevention and treatment.

Citation: GUO Yang, GUO Guanyi, CAO Xueshan. Progress and application of cohort multiple randomized controlled trial: a systematic review. Chinese Journal of Evidence-Based Medicine, 2019, 19(12): 1470-1476. doi: 10.7507/1672-2531.201908030 Copy

  • Previous Article

    Traditional Chinese medicine treatment for essential hypertension from 2015 to 2019: an overview of systematic reviews
  • Next Article

    Considerations and suggestions for standardizing clinical practice guideline of traditional Chinese patent medicine-chronic renal disease as an example